1410 related articles for article (PubMed ID: 32442437)
1. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.
Tundo GR; Sbardella D; Santoro AM; Coletta A; Oddone F; Grasso G; Milardi D; Lacal PM; Marini S; Purrello R; Graziani G; Coletta M
Pharmacol Ther; 2020 Sep; 213():107579. PubMed ID: 32442437
[TBL] [Abstract][Full Text] [Related]
2. [The proteasome - structural aspects and inhibitors: a second life for a validated drug target].
Reboud-Ravaux M
Biol Aujourdhui; 2021; 215(1-2):1-23. PubMed ID: 34397372
[TBL] [Abstract][Full Text] [Related]
3. A Practical Review of Proteasome Pharmacology.
Thibaudeau TA; Smith DM
Pharmacol Rev; 2019 Apr; 71(2):170-197. PubMed ID: 30867233
[TBL] [Abstract][Full Text] [Related]
4. Targeting the ubiquitin proteasome system in haematological malignancies.
Crawford LJ; Irvine AE
Blood Rev; 2013 Nov; 27(6):297-304. PubMed ID: 24183816
[TBL] [Abstract][Full Text] [Related]
5. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.
Narayanan S; Cai CY; Assaraf YG; Guo HQ; Cui Q; Wei L; Huang JJ; Ashby CR; Chen ZS
Drug Resist Updat; 2020 Jan; 48():100663. PubMed ID: 31785545
[TBL] [Abstract][Full Text] [Related]
6. Ubiquitin-proteasome system as a target for anticancer treatment-an update.
Kim YJ; Lee Y; Shin H; Hwang S; Park J; Song EJ
Arch Pharm Res; 2023 Jul; 46(7):573-597. PubMed ID: 37541992
[TBL] [Abstract][Full Text] [Related]
7. Targeting the ubiquitin proteasome system: beyond proteasome inhibition.
Xolalpa W; Perez-Galan P; Rodríguez MS; Roué G
Curr Pharm Des; 2013; 19(22):4053-93. PubMed ID: 23181575
[TBL] [Abstract][Full Text] [Related]
8. The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors.
Johnson DE
Endocr Relat Cancer; 2015 Feb; 22(1):T1-17. PubMed ID: 24659480
[TBL] [Abstract][Full Text] [Related]
9. Targeting the ubiquitin+proteasome system in solid tumors.
Driscoll JJ; Woodle ES
Semin Hematol; 2012 Jul; 49(3):277-83. PubMed ID: 22726552
[TBL] [Abstract][Full Text] [Related]
10. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment.
Park J; Cho J; Song EJ
Arch Pharm Res; 2020 Nov; 43(11):1144-1161. PubMed ID: 33165832
[TBL] [Abstract][Full Text] [Related]
11. The ubiquitin proteasome system as a potential target for the treatment of neurodegenerative diseases.
Ying Z; Wang H; Wang G
Curr Pharm Des; 2013; 19(18):3305-14. PubMed ID: 23151138
[TBL] [Abstract][Full Text] [Related]
12. Proteasome, a Promising Therapeutic Target for Multiple Diseases Beyond Cancer.
Cao Y; Zhu H; He R; Kong L; Shao J; Zhuang R; Xi J; Zhang J
Drug Des Devel Ther; 2020; 14():4327-4342. PubMed ID: 33116419
[TBL] [Abstract][Full Text] [Related]
13. The Ubiquitin-Proteasome Pathway and Resistance Mechanisms Developed Against the Proteasomal Inhibitors in Cancer Cells.
Yerlikaya A; Kanbur E
Curr Drug Targets; 2020; 21(13):1313-1325. PubMed ID: 32448101
[TBL] [Abstract][Full Text] [Related]
14. The Small Molecules Targeting Ubiquitin-Proteasome System for Cancer Therapy.
Ao N; Chen Q; Liu G
Comb Chem High Throughput Screen; 2017; 20(5):403-413. PubMed ID: 28699494
[TBL] [Abstract][Full Text] [Related]
15. Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment.
Yang H; Chen X; Li K; Cheaito H; Yang Q; Wu G; Liu J; Dou QP
Semin Cancer Biol; 2021 Jan; 68():105-122. PubMed ID: 31883910
[TBL] [Abstract][Full Text] [Related]
16. The role of the ubiquitin proteasome system in lymphoma.
Suh KS; Tanaka T; Sarojini S; Nightingale G; Gharbaran R; Pecora A; Goy A
Crit Rev Oncol Hematol; 2013 Sep; 87(3):306-22. PubMed ID: 23541070
[TBL] [Abstract][Full Text] [Related]
17. Multiple myeloma cells are exceptionally sensitive to heat shock, which overwhelms their proteostasis network and induces apoptosis.
Sha Z; Goldberg AL
Proc Natl Acad Sci U S A; 2020 Sep; 117(35):21588-21597. PubMed ID: 32817432
[TBL] [Abstract][Full Text] [Related]
18. The Ubiquitin-Proteasome Pathway and Epigenetic Modifications in Cancer.
Yerlikaya A; Kanbur E; Stanley BA; Tümer E
Anticancer Agents Med Chem; 2021; 21(1):20-32. PubMed ID: 32781973
[TBL] [Abstract][Full Text] [Related]
19. Positioning of proteasome inhibitors in therapy of solid malignancies.
Roeten MSF; Cloos J; Jansen G
Cancer Chemother Pharmacol; 2018 Feb; 81(2):227-243. PubMed ID: 29184971
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
Chen D; Frezza M; Schmitt S; Kanwar J; Dou QP
Curr Cancer Drug Targets; 2011 Mar; 11(3):239-53. PubMed ID: 21247388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]